Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV001290895 | SCV001479162 | likely pathogenic | Neurofibromatosis, type 1 | 2020-10-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004558295 | SCV005048559 | likely pathogenic | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-07-13 | criteria provided, single submitter | clinical testing | The p.L578R variant (also known as c.1733T>G), located in coding exon 16 of the NF1 gene, results from a T to G substitution at nucleotide position 1733. The leucine at codon 578 is replaced by arginine, an amino acid with dissimilar properties. This alteration has been reported in multiple individuals meeting NIH criteria for neurofibromatosis type I (NF1) (Ambry internal data; Kluwe L et al. J Med Genet, 2003 May;40:368-71; Ko JM et al. Pediatr Neurol, 2013 Jun;48:447-53; Wang X et al. Genes Chromosomes Cancer, 2018 Jan;57:19-27). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
Uni |
RCV000059156 | SCV000090685 | not provided | not provided | no assertion provided | not provided |